Search results for: Baylor University Medical Center

Baylor University Medical Center performs 200th islet cell transplant

Baylor University Medical Center at Dallas, part of Baylor Scott & White Health, recently performed its 200th islet cell transplant in a patient with chronic pancreatitis, making Baylor Dallas one of the four largest islet cell transplant programs in the nation in terms of volume. Baylor Dallas is the only hospital in North Texas that performs these transplants.

Read more

Interstitial lung disease program focuses on comprehensive, individualized patient care

Interstitial lung disease or diffuse parenchymal lung disease comprises a large group of more than 150 heterogeneous disorders. As a result, patients with these disorders are a difficult group to treat because many of the therapies are individualized to each patient. The Interstitial Lung Disease Clinic at Baylor University Medical Center, part of Baylor Scott & White Health, provides comprehensive care to patients with ILD.

Read more

Treatment of frailty can improve outcomes for transplant recipients

The impact of frailty on outcomes for organ transplant recipients is gaining widespread attention in transplant programs around the world. In numerous studies, frailty has been associated with increased length of stay,  increased hospitalizations, increased costs, and increased mortality.

Read more

In Barrett’s epithelial cells, weakly acidic bile causes DNA damage with response and repair mediated by p38

Gastroesophageal reflux disease (GERD) can cause Barrett’s esophagus, a change in the lining of the esophagus that predisposes to a type of cancer called esophageal adenocarcinoma.  It is thought that the reflux of strong acid and bile salts from the stomach into the esophagus contributes to the development of this cancer.  In an attempt to prevent esophageal adenocarcinoma, physicians prescribe proton pump inhibitors (PPIs) for patients with Barrett’s esophagus.  These PPIs reduce the amount of acid produced by the stomach, but they do not stop the reflux of gastric contents into the esophagus.  The gastric contents of patients taking PPIs are weakly acidic and they contain bile salts, and our team at Baylor Scott & White Research Institute’s Center for Esophageal Research were concerned that this material still might be damaging to the esophagus.  

Read more